Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12554MR)

This product GTTS-WQ12554MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam NGF gene. The antibody can be applied in Osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001194950.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 403402
UniProt ID F1PDQ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12554MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9713MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ10842MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ15769MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ6960MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ2700MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ15464MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ5971MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ2053MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AH-PD1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW